• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过脂肪酸结合口袋靶向刺突糖蛋白的新型抗SARS-CoV-2病毒支架的计算机发现

In Silico Discovery of a Novel Antiviral Scaffold for SARS-CoV‑2 Targeting the Spike Glycoprotein through the Fatty Acid Binding Pocket.

作者信息

Queirós-Reis Luís, Kaarbo̷ Mari, Al-Baldawi Huda, Alvites Rui, Maurício Ana Colette, Brancale Andrea, Bassetto Marcella, Mesquita João R

机构信息

Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, Porto 4050-313, Portugal.

Department of Microbiology, Oslo University Hospital, Oslo 0424, Norway.

出版信息

ACS Omega. 2025 Jun 4;10(23):24117-24132. doi: 10.1021/acsomega.4c10519. eCollection 2025 Jun 17.

DOI:10.1021/acsomega.4c10519
PMID:40547706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12177760/
Abstract

The key viral protein for infection by SARS-CoV-2 is the spike glycoprotein (S protein), mediating entry into host cells, which therefore represents a strong focus for the development of targeted therapeutics. In this work, we explored the fatty acid binding pocket within the S protein, which stabilizes an inactive conformation and disrupts cell recognition and infection. To explore the potential of this site as a drug target, molecular dynamics simulations were performed, followed by a docking-based virtual screening of commercial druglike compounds. This in silico procedure enabled the identification of potential inhibitors of SARS-CoV-2 cell infection, likely by stabilizing an inactive spike conformation, detected in binding assays, although further experiments are required to directly confirm this action. The antiviral effect of the virtual hits was analyzed in cell-based assays, and one molecule displayed a low micromolar activity. Starting from the best antiviral compound found, structural analogues were purchased and evaluated in antiviral assays. An increase in activity was observed for multiple analogues, with the strongest antiviral compound showing submicromolar activity and low cytotoxicity. The successful identification of a new antiviral scaffold through in silico studies might pave the way for the further development of antivirals against SARS-CoV-2 and shows the reliability of the methodologies applied.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的关键病毒蛋白是刺突糖蛋白(S蛋白),它介导病毒进入宿主细胞,因此成为靶向治疗药物开发的重点。在这项研究中,我们探索了S蛋白内的脂肪酸结合口袋,该口袋稳定了一种无活性构象并破坏细胞识别和感染。为了探究该位点作为药物靶点的潜力,我们进行了分子动力学模拟,随后对商业类药物化合物进行了基于对接的虚拟筛选。这种计算机模拟方法能够识别出可能通过稳定一种在结合试验中检测到的无活性刺突构象来抑制SARS-CoV-2细胞感染的潜在抑制剂,不过还需要进一步实验来直接证实这种作用。在基于细胞的试验中分析了虚拟筛选命中化合物的抗病毒效果,其中一种分子表现出低微摩尔活性。从找到的最佳抗病毒化合物出发,购买了其结构类似物并在抗病毒试验中进行评估。多个类似物的活性有所增加,最强的抗病毒化合物表现出亚微摩尔活性和低细胞毒性。通过计算机模拟研究成功鉴定出一种新的抗病毒支架,这可能为进一步开发抗SARS-CoV-2病毒药物铺平道路,并显示了所应用方法的可靠性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/974e8ab82138/ao4c10519_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/305e1a5fe517/ao4c10519_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/204d10fa4d36/ao4c10519_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/6a7a1855794a/ao4c10519_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/1d963620bb2a/ao4c10519_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/e5ea979dfc9a/ao4c10519_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/38a09a713c19/ao4c10519_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/fa0e761253d2/ao4c10519_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/f8b90211a9b3/ao4c10519_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/3243e27c55a9/ao4c10519_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/b9077d9cde5b/ao4c10519_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/f14154be7840/ao4c10519_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/72ffa62dc96c/ao4c10519_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/d8115c9ded1e/ao4c10519_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/7f3dfe9706dd/ao4c10519_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/58bb851f6a53/ao4c10519_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/54a3417ad118/ao4c10519_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/974e8ab82138/ao4c10519_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/305e1a5fe517/ao4c10519_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/204d10fa4d36/ao4c10519_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/6a7a1855794a/ao4c10519_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/1d963620bb2a/ao4c10519_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/e5ea979dfc9a/ao4c10519_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/38a09a713c19/ao4c10519_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/fa0e761253d2/ao4c10519_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/f8b90211a9b3/ao4c10519_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/3243e27c55a9/ao4c10519_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/b9077d9cde5b/ao4c10519_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/f14154be7840/ao4c10519_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/72ffa62dc96c/ao4c10519_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/d8115c9ded1e/ao4c10519_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/7f3dfe9706dd/ao4c10519_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/58bb851f6a53/ao4c10519_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/54a3417ad118/ao4c10519_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8142/12177760/974e8ab82138/ao4c10519_0017.jpg

相似文献

1
In Silico Discovery of a Novel Antiviral Scaffold for SARS-CoV‑2 Targeting the Spike Glycoprotein through the Fatty Acid Binding Pocket.通过脂肪酸结合口袋靶向刺突糖蛋白的新型抗SARS-CoV-2病毒支架的计算机发现
ACS Omega. 2025 Jun 4;10(23):24117-24132. doi: 10.1021/acsomega.4c10519. eCollection 2025 Jun 17.
2
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Incentives for preventing smoking in children and adolescents.预防儿童和青少年吸烟的激励措施。
Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD008645. doi: 10.1002/14651858.CD008645.pub3.
8
Determinants of susceptibility to SARS-CoV-2 infection in murine ACE2.小鼠血管紧张素转换酶2(ACE2)对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染易感性的决定因素。
J Virol. 2025 Jun 17;99(6):e0054325. doi: 10.1128/jvi.00543-25. Epub 2025 May 12.
9
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
10
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.

本文引用的文献

1
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.美国国立卫生研究院 COVID-19 治疗指南专家组:观点与经验教训。
Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1.
2
Exploring the Fatty Acid Binding Pocket in the SARS-CoV-2 Spike Protein - Confirmed and Potential Ligands.探索 SARS-CoV-2 刺突蛋白中的脂肪酸结合口袋——已确认和潜在配体。
J Chem Inf Model. 2023 Dec 11;63(23):7282-7298. doi: 10.1021/acs.jcim.3c00803. Epub 2023 Nov 22.
3
Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus.
用于分离新冠病毒临床分离株和产生重组病毒的细胞培养系统。
iScience. 2023 May 19;26(5):106634. doi: 10.1016/j.isci.2023.106634. Epub 2023 Apr 10.
4
In Silico Discovery of Small Molecule Modulators Targeting the Achilles' Heel of SARS-CoV-2 Spike Protein.通过计算机模拟发现靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白弱点的小分子调节剂
ACS Cent Sci. 2023 Feb 8;9(2):252-265. doi: 10.1021/acscentsci.2c01190. eCollection 2023 Feb 22.
5
The free fatty acid-binding pocket is a conserved hallmark in pathogenic β-coronavirus spike proteins from SARS-CoV to Omicron.游离脂肪酸结合口袋是 SARS-CoV 到奥密克戎等致病β-冠状病毒刺突蛋白中的一个保守特征。
Sci Adv. 2022 Nov 25;8(47):eadc9179. doi: 10.1126/sciadv.adc9179. Epub 2022 Nov 23.
6
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.SARS-CoV-2 奥密克戎是一种具有改变的细胞进入途径的免疫逃逸变体。
Nat Microbiol. 2022 Aug;7(8):1161-1179. doi: 10.1038/s41564-022-01143-7. Epub 2022 Jul 7.
7
Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor.棕榈酰乙醇酰胺(PEA)通过与 S 蛋白和 ACE-2 受体相互作用抑制 SARS-CoV-2 进入。
Viruses. 2022 May 17;14(5):1080. doi: 10.3390/v14051080.
8
Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein.合成病毒粒子揭示了 SARS-CoV-2 刺突糖蛋白的脂肪酸偶联适应性免疫原性。
Nat Commun. 2022 Feb 14;13(1):868. doi: 10.1038/s41467-022-28446-x.
9
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.SARS-CoV-2 Delta 突变株 P681R 增强了融合性和致病性。
Nature. 2022 Feb;602(7896):300-306. doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25.
10
SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response.SARS-CoV-2 病毒-宿主相互作用:目前可用的结构以及变异体出现对感染性和免疫反应的影响。
Int J Mol Sci. 2021 Oct 7;22(19):10836. doi: 10.3390/ijms221910836.